莫索尼定对麻醉大鼠血流动力学的影响

目的观察国产盐酸莫索尼定对麻醉大鼠血流动力学的影响。方法采用麻醉Wistar大鼠动脉插管法,测定其血流动力学指标。结果给药后,HR、SBP轻度下降(P>0.05);DBP明显下降(P<0.01)的同时,±dp/dtmax,tdp/dtmax、Vpm及Vmax明显降低(P<0.01),且呈剂量依赖性。结论莫索尼定对心肌收缩性与舒张性均有明显的抑制作用;其降压作用与外周阻力下降有关。     

Effects of two benzimidazoles as proton pump inhibitors on water immersion stress-induced gastric ulcers in rats.

This study was designed to clarify effects of proton pump inhibitors, E-3810(2-([4-(3-methoxypropoxy)-3methylpyridine-2-yl]methyl- sulfinyl)-1H-benzimidazol sodium salt) and omeprazole (CAS 73590-58-6), on water immersion stress-induced gastric ulcers in relation to mucosal prostaglandins (PGs) and leukotrienes (LTs). Mucosal PGs were measured by high performance liquid chromatography (HPLC). In untreated rats, 4 kinds of PGs, i.e., 6-keto-PGF1 alpha, PGF2 alpha, PGE2 and PGD2 were detected in gastric mucosa, but no LTs were detected. Water immersion stress for 6 h caused severe hemorrhagic lesions in the fundic portion and, concomitantly, significant decreases in mucosal PG levels. On the other hand, LTC4 and LTD4 were detected after 6 h stress treatment, though LTB4 and LTE4 were not detected throughout the experiments. Peptide-LT (the sum of LTC4 and LTD4) levels were 23.5 +/- 3.2 ng/g tissue 6 h after water immersion stress. Administration of 20 mg/kg of E-3810 or 20 mg/kg of omeprazole mitigated gastric lesions and increases in the mucosal peptide-LT levels, but dit not improve the decrease in mucosal PGs.     

Effects of nitric oxide-related compounds and carperitide on hemodynamics and hematocrit in anesthetized rats.

Sodium nitroprusside, nitroglycerin and carperitide (alpha-human ANP) all reduced mean blood pressure, but only carperitide increased the hematocrit in rats with bilateral renal artery- and ureter-ligation. NG-Monomethyl-L-arginine, a selective inhibitor of nitric oxide synthesis, elevated the mean blood pressure but did not change the hematocrit significantly. These findings suggest that ANP has a physiological role in regulating circulatory blood volume distinct from that of NO, although both increase intracellular cyclic GMP in the vasculature.     

Effects of gastric proton pump inhibitors on gastric secretion and peptic ulcers

This is a review article on newly developed antisecretory drugs which are now called proton pump inhibitors. Gastric H+ is secreted from the secretory membrane of parietal cells into the lumen of the stomach, using energy obtained by destructing ATP with H+, K+-ATPase (proton pump). Various substituted benzimidazoles such as timoprazole, picoprazole, omeprazole, or NC-1300 potently inhibits this proton pump at pH 6.0, thereby resulting in a strong inhibition of gastric H+ secretion. This inhibition of H+ secretion lasts for a long period, ie, 1-3 days after a single oral or intraduodenal administration, both in experimental animals and humans. This long lasting activity of these compounds appears to be due to their accumulation in the parietal cells because of their low pKa values (about 4.0). Proton pump inhibitors dose-dependently inhibit the development of various experimental ulcers and accelerate healing of chronic gastric ulcers in animals. Since these compounds also potently inhibit the development of HCl X ethanol or HCl X aspirin-induced gastric ulcers in animals, they are considered to have a cytoprotective activity. Some of the compounds (e.g., omeprazole) afforded a complete healing of peptic ulcers in man when it was given once daily for 2 to 4 weeks, without any adverse effects. Therefore, these proton pump inhibitors appear to be promising drugs for the treatment of peptic ulcer diseases.     

质子泵抑制剂的胃黏膜保护作用与环氧化酶-2表达

目的　探讨质子泵抑制剂 (PPIs)的胃黏膜保护作用与环氧化酶 2 (COX 2 )表达的关系。方法　♂SD大鼠ig给予雷巴拉唑、奥美拉唑或兰索拉唑 5 0mg·kg-1·d-1,对照组ig给予质量分数为 0 5 %羧基纤维素 5ml·kg-1·d-1,连续 2wk。Westernblot和免疫组化检测胃黏膜COX 2表达。酶免疫方法测定胃黏膜中前列腺素E2 (PGE2 )水平 ,评价兰索拉唑和特异性COX 2抑制剂NS 3 98对乙醇所致大鼠胃黏膜损伤的影响。结果　 3种PPI均增加大鼠胃黏膜COX 2的表达。兰索拉唑呈剂量依赖性地增加胃黏膜中PGE2 含量 ,有效地减轻乙醇对胃黏膜的损伤作用。NS 3 98有效地阻断了兰索拉唑诱导的PGE2 合成及胃黏膜保护作用。结论　PPIs通过诱导胃黏膜COX 2表达 ,增加PGE2 合成而发挥胃黏膜保护作用     

Effects of the new angiotensin-converting enzyme inhibitor imidapril on renal hemodynamics and function in anesthetized dogs.

The effects of a new angiotensin-converting enzyme (ACE) inhibitor, imidapril hydrochloride ((-)-(4S)-3-[(2S)-2- [[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]propionyl]- 1-methyl-2-oxoimidazolidine-4-carboxylic acid hydrochloride, imidapril, TA-6366, CAS 89396-94-1) and of its active metabolite, 6366 A (CAS 89371-44-8) on renal function were studied in anesthetized dogs and compared to the effects of enalapril and its active metabolite, enalaprilat. Intravenous (i.v.) administration of 6366 A at 30 micrograms/kg strongly inhibited angiotensin I-induced renal vasoconstrictive and pressor responses. 6366 A promptly lowered blood pressure and renal vascular resistance, and caused clear increases in renal blood flow and glomerular filtration rate. It also increased urine volume and urinary excretion of sodium and chloride. These renal effects were also produced by intraduodenal (i.d.) administration of 2 mg/kg of imidapril. However, the effects of i.d. imidapril began later, developed gradually and reached a plateau after 2 to 3 h. Enalaprilat (30 micrograms/kg i.v.) and enalapril (2 mg/kg i.d.) had renal effects similar to 6366 A and imidapril. In conclusion, the ACE inhibitor imidapril has beneficial effects on renal function via its active metabolite, and the effects appear to be essentially identical to those of enalapril.     

Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats

T-593 (osutidine, CAS 140695-21-2) is a new anti-ulcer agent that consists of two enantiomers, (+)-(R)-T-593 and (-)-(S)-T-593. The present study was designed to investigate the effects of T-593, (+)-(R)-T-593 and (-)-(S)-T-593 on ethanol-induced gastric damage in rats. Rats were given intraperitoneal administration of vehicle, racemic T-593, (+)-(R)-T-593 or (-)-(S)-T-593. 30 min later, the rats intragastrically received a 1-ml solution of 40% ethanol, and 30 min thereafter, they were sacrificed for assessment of gastric damage. Gastric hemodynamics were assessed by reflectance spectrophotometry and laser Doppler flowmetry during the experiment. Gastric damage was significantly suppressed by racemic T-593 in a dose-dependent manner. While 60 mg/kg of (+)-(R)-T-593 and (-)-(S)-T-593 also suppressed ethanol-induced gastric injury, the same dose of racemic T-593 exerted the most potent anti-ulcerative activity. Both (+)-(R)-T-593 and racemic T-593 increased gastric mucosal blood flow and abolished gastric mucosal blood flow stasis induced by 40% ethanol. Although (-)-(S)-T-593, which antagonizes histamine H2-receptors, exerts an antiulcerative effect, (+)-(R)-T-593 also protects the gastric mucosa from ethanol-induced injury, possibly by influencing gastric mucosal hemodynamics. Thus racemic T-593 may protect the gastric mucosa by antagonizing H2-receptors and by enhancing gastric circulation in rats.     

Influence of proton pump inhibitors on dexamethasone-induced gastric mucosal damage in rats

The present study was designed to compare the curative role of proton pump inhibitors, omeprazole, rabeprazole and lansoprazole against dexamethasone-induced ulcer model. Dexamethasone (5 mg/kg/day) was used as an ulcerogen. Dexamethasone suspended in 1% CMC in water was given orally to all rats. Omeprazole (20 mg/kg), rabeprazole (20 mg/kg), and lansoprazole (20 mg/kg) were administered by oral route 30 minutes prior to dexamethasone for ulcer protective studies, gastric secretion and mucosal studies. Effects of proton pump inhibitors were determined by the evaluation of various biochemical parameters such as estimation of myeloperoxidase, cortisol, alkaline phosphatase, malondialdehyde, endogenous anti-oxidants like superoxide dismutase, catalase and reduced glutathione. In dexamethasone induced ulcer model, omeprazole showed significant decrease in malondialdehyde, myeloperoxidase, alkaline phosphatase level and increase in superoxide dismutase, catalase and reduced glutathione level as compared to rabeprazole and lansoprazole. Omeprazole showed significant reduction in cortisol content where as rabeprazole and lansoprazole did not show significant changes as compared to control. The result indicates that omeprazole is the most effective and selective proton pump inhibitor in dexamethasone induced ulcer model as compared to rabeprazole and lansoprazole.     

异莲心碱对麻醉大鼠血流动力学及平滑肌收缩反应的影响

异莲心碱2.5-10 mg·kg^-1 iv可剂量依赖性地一过性轻度降低麻醉大鼠心率, 收缩动脉压, 平均动脉压, 舒张动脉压, 左室收缩压, 左室压力最大变化速率,而对左室舒张末压无显著影响. 异莲心碱使甲氧明所致兔主动脉环和大鼠肛尾肌收缩的量 效曲线平行右移,最大反应不降低,pA₂分别为6.25和6.15,对高K⁺所致兔主动脉环收缩也有明显抑制作用. 异莲心碱还明显抑制去甲肾上腺素引起的兔主动脉环依内钙和外钙的收缩反应. 结果表明,异莲心碱对α₁受体有较为明显的阻断作用,并可抑制该受体引起的内钙释放和外钙内流,对电压依赖性钙通道也有阻滞作用. 异莲心碱的一过性轻度降压和抗心律失常作用可能与这些均有关.     

Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo

The inhibitory effects of IY-81149 (2-[[(4-methoxy-3-methyl)-2- pyridinyl]methyl-sulfinyl]-5-(1H-pyrol-1-yl)-1H-benzimidazole, CAS 172152-36-2), a newly developed proton pump inhibitor (PPI) on gastric acid secretion were investigated in vitro and in vivo. In rabbit parietal cell preparation, IY-81149 irreversibly inhibited H+/K(+)-ATPase in dose-dependent manner with an IC50 of pump inhibitory activity of 6.0 x 10(-6) mol/l and that of omeprazole (CAS 73590-58-6) was 1 x 10(-4) mol/l at pH 7.4. On cumulation of 14C-aminopyrine in histamine stimulated parietal cells, the IC50 of IY-81149 was 9.0 x 10(-9) mol/l and that of omeprazole was 1.9 x 10(-8) mol/l. The inhibition rates of IY-81149 and omeprazole at a concentration of 1 x 10(-9) mol/l in human parietal cells were 137% and 64%, respectively. In pylorus-ligated rats, IY-81149 showed a 2-3 times stronger inhibitory activity than omeprazole against gastric acid secretion. The ED50 of IY-81149 and omeprazole administered intraduodenally was 1.6 mg/kg and 3.8 mg/kg. In the case of oral administration, the ED50 of IY-81149 and omeprazole was 1.94 mg/kg and 5.64 mg/kg, respectively. But after 24 h administration, the anti-secretory activity of IY-81149 was lower than that of omeprazole at all doses tested. In anesthetized rats, IY-81149 dose-dependently increased gastric pH which was lowered by histamine infusion. In the case of i.v. injection, the ED50 of IY-81149 and omeprazole was 1.2 and 1.4 mg/kg and in the case of i.d. administration, the ED50 of IY-81149 and omeprazole was 3.9 and 4.1 mg/kg, respectively. IY-81149 also significantly inhibited pentagastrin-stimulated gastric secretion. Its ED50 was 2.1 mg/kg and that of omeprazole was 3.5 mg/kg with i.d. administration. In the case of i.v. injection, IY-81149 was equipotent to omeprazole. IY-81149 also inhibited gastric acid secretion strongly in fistular rats. The ED50 of IY-81149 administered intraduodenally was 0.43 mg/kg and that of omeprazole was 0.68 mg/kg. In Heidenhain pouch dogs, the acid output was completely blocked at 0.3 mg/kg, 135 min after i.v. administration. Omeprazole showed a similar effect as IY-81149. The histamine induced increase of acid output in the Heidenhain pouch dog was blocked by 71% 150 min after oral administration of enteric-coated IY-81149 at a dose of 3 mg/kg, and omeprazole showed similar effects. In conclusion, IY-81149 revealed the characteristics as a strong proton pump inhibitor, and its potency against gastric acid secretion was superior to that of the reference drug, omeprazole.     

Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats

The effects of (+/-)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy-2- pyridyl]methyl]sulfinyl]-1H-benzimidazole (lansoprazole, AG-1749) and famotidine on various experimental ulcers in rats were compared. AG-1749 inhibited reflux esophagitis; gastric lesions induced by water-immersion stress, aspirin or ethanol; and duodenal ulcers induced by cysteamine or mepirizole in a dose-dependent manner: the ID50 values were 0.7, 2.4, 0.7, 8.5, 1.1 and 0.3 mg/kg, p.o. or i.d., respectively. Famotidine inhibited reflux esophagitis with an ID50 value of 12.9 mg/kg, but did not cause 50% inhibition of ethanol-induced gastric lesions even at 100 mg/kg, although it showed almost the same or a little stronger potency on other experimental ulcers: ID50 values were 0.3-1.4 mg/kg. Significant aggravation of ethanol- or water-immersion stress-induced lesions was observed in rats given famotidine at 30 mg/kg twice daily for 4 days, but not in rats given AG-1749 at 10 mg/kg twice daily. Administration of AG-1749 for 14 consecutive days markedly accelerated the healing of acetic acid-induced gastric and duodenal ulcers, and the healing effect was significant at 10 and 30 mg/kg/day, p.o. Famotidine also accelerated the healing of ulcers, but its potency was less than that of AG-1749. The results of this study indicate that although AG-1749 is slightly less potent than famotidine in inhibiting acutely induced gastroduodenal lesions, this agent is superior to famotidine in promoting the healing of ulcers and in inhibiting reflux esophagitis and ethanol-induced gastric lesions.     

苯并咪唑类质子泵抑制剂的药理学研究进展

苯丙咪唑类质子泵抑制剂(Protonpumpinhibitor,PPI)雷贝拉唑、奥美拉唑、兰索拉唑和泮托拉唑在肝脏中不同程度地被细胞色素P450(CYP)同功酶代谢(参与CYP代谢的主要同功酶为CYP2C19和CYP3A4),它们药物代谢和药代动力学的不同会对其药效学(如抑制胃酸分泌,对胃泌素的影响)及可能出现的药物相互作用产生不同影响。1CYP与基因多态性对PPI药效的影响PPI在肝脏中的氧化代谢是由特异性或选择性CYP同功酶来催化的,根据基因多态性表达产物又可将CYP同功酶进一步分为不同类型。参与PPI代谢的同功酶主要有CYP2C19和CYP3A4。CYP2C19…     

荭草苷对麻醉犬心功能与血流动力学的影响

目的 研究荭草苷对麻醉犬心功能与血流动力学的影响.方法 麻醉犬开胸,测定心脏血流动力学参数,并分离冠状动脉左旋支,放置探头测量冠脉血流量,同步测量心输出量.结果 0.5、1.0、2.0 mg·kg-1荭草苷可降低麻醉犬的血压,减少心肌耗氧量以及减慢心率,降低左室舒张末期压,左心室内压最大上升和下降速率,同时增加冠脉血流量.结论 荭草苷通过减少心肌耗氧量,降低左室舒张末期压及左心室内压最大上升和下降速率,使冠脉流量增加等环节发挥改善麻醉犬心功能与血流动力学的作用.     

质子泵抑制剂的合理应用及其影响因素

目的探讨质子泵抑制剂(PPI)作用的影响因素,促进临床合理用药。方法综述PPI的作用原理及临床应用研究,探讨质子泵抑制剂的药效影响因素。结果 PPI的药效与用药时间、患者的情绪及基因多态性等多种因素有关。结论临床合理用药方案的制定应综合考虑多方面因素。     

Effect of kavinton on systemic and regional hemodynamics in waking and anesthetized rats

The effect of cavinton (vinpocetine) on the systemic and regional hemodynamic parameters was studied by the radioactive microsphere technique in experiments on conscious and anesthetized rats. Intravenous administration of cavinton (10 mg/kg) was followed by the development of hypotension and bradycardia in conscious and anesthetized animals. Administration of cavinton to anesthetized rats increased the blood flow both in the brain and in most internal organs. In conscious animals the drug failed to increase the cerebral blood flow but increased the blood flow in the internal organs. It is suggested that dilation of the cerebral vessels under the influence of cavinton only in anesthetized rats could be related to a higher initial resistance of the cerebral vessels in anesthetized animals as compared with conscious ones.